JP2023531252A5 - - Google Patents
Info
- Publication number
- JP2023531252A5 JP2023531252A5 JP2022580096A JP2022580096A JP2023531252A5 JP 2023531252 A5 JP2023531252 A5 JP 2023531252A5 JP 2022580096 A JP2022580096 A JP 2022580096A JP 2022580096 A JP2022580096 A JP 2022580096A JP 2023531252 A5 JP2023531252 A5 JP 2023531252A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cancer
- chain containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025283168A JP2026053657A (ja) | 2020-06-26 | 2025-12-25 | 抗ｂ７－ｈ３抗体を含む抗体－薬物コンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044764P | 2020-06-26 | 2020-06-26 | |
| US63/044,764 | 2020-06-26 | ||
| PCT/IB2021/000445 WO2021260438A1 (en) | 2020-06-26 | 2021-06-25 | Antibody-drug conjugates comprising anti-b7-h3 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025283168A Division JP2026053657A (ja) | 2020-06-26 | 2025-12-25 | 抗ｂ７－ｈ３抗体を含む抗体－薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531252A JP2023531252A (ja) | 2023-07-21 |
| JP2023531252A5 true JP2023531252A5 (enExample) | 2024-07-02 |
| JP7798811B2 JP7798811B2 (ja) | 2026-01-14 |
Family
ID=79282029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580096A Active JP7798811B2 (ja) | 2020-06-26 | 2021-06-25 | 抗ｂ７－ｈ３抗体を含む抗体－薬物コンジュゲート |
| JP2025283168A Pending JP2026053657A (ja) | 2020-06-26 | 2025-12-25 | 抗ｂ７－ｈ３抗体を含む抗体－薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025283168A Pending JP2026053657A (ja) | 2020-06-26 | 2025-12-25 | 抗ｂ７－ｈ３抗体を含む抗体－薬物コンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12168060B2 (enExample) |
| EP (1) | EP4171655A4 (enExample) |
| JP (2) | JP7798811B2 (enExample) |
| KR (1) | KR20230028793A (enExample) |
| CN (2) | CN116999571A (enExample) |
| AU (1) | AU2021297036A1 (enExample) |
| BR (1) | BR112022026401A2 (enExample) |
| CA (1) | CA3182602A1 (enExample) |
| IL (1) | IL299362A (enExample) |
| MX (1) | MX2022016180A (enExample) |
| WO (1) | WO2021260438A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019229536A2 (en) | 2018-05-29 | 2019-12-05 | Intocell, Inc. | Novel benzodiazepine derivatives and uses thereof |
| CA3118026A1 (en) | 2018-10-31 | 2020-05-07 | Intocell, Inc. | Fused heterocyclic benzodiazepine derivatives and uses thereof |
| KR20220108783A (ko) * | 2019-12-02 | 2022-08-03 | 주식회사 인투셀 | 분자 접합과 관련된 조성물 및 방법 |
| AU2021297036A1 (en) | 2020-06-26 | 2023-01-19 | Intocell, Inc. | Antibody-drug conjugates comprising anti-b7-h3 antibodies |
| KR20240125927A (ko) * | 2021-12-28 | 2024-08-20 | 베이진 스위찰랜드 게엠베하 | 항체 약물 접합체 |
| WO2023173393A1 (zh) * | 2022-03-18 | 2023-09-21 | 北京天广实生物技术股份有限公司 | 结合b7-h3的抗体及其用途 |
| WO2024092219A1 (en) * | 2022-10-28 | 2024-05-02 | Eli Lilly And Company | Self-hydrolyzing maleimides for bioconjugation |
| TW202438527A (zh) * | 2023-03-17 | 2024-10-01 | 瑞士商百濟神州瑞士有限責任公司 | 抗b7h3抗體以及其使用方法 |
| WO2024225838A1 (ko) * | 2023-04-28 | 2024-10-31 | 주식회사 에이비켐바이오 | 균일한 dar을 갖는 말레이미드 함유 링커를 포함하는 항체-약물 중합체의 제조방법 |
| WO2024235120A1 (zh) * | 2023-05-12 | 2024-11-21 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物及其制备方法和用途 |
| CN116949044B (zh) * | 2023-09-20 | 2023-12-12 | 北京炫景瑞医药科技有限公司 | 一种双链寡链核苷酸、包含该双链寡核苷酸的缀合物以及它们的用途 |
| CN117777296B (zh) * | 2024-02-28 | 2024-05-28 | 北京肿瘤医院(北京大学肿瘤医院) | B7h3亲和体及其诊疗核素标记物的制备方法与应用 |
| WO2025237246A1 (en) * | 2024-05-11 | 2025-11-20 | Westlake Laboratory Of Life Sciences And Biomedicine | Novel covalent protein and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3193933B1 (en) * | 2014-09-17 | 2021-04-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd276 antibodies (b7h3) |
| CA3020864A1 (en) * | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
| TWI762487B (zh) | 2016-06-08 | 2022-05-01 | 美商艾伯維有限公司 | 抗-b7-h3抗體及抗體藥物結合物 |
| UA125593C2 (uk) * | 2017-03-31 | 2022-04-27 | Джянгсу Хенгруй Медісін Ко., Лтд. | Антитіло в7-н3, його антигензв'язуючий фрагмент та його медичне застосування |
| EP3649142A4 (en) * | 2017-07-04 | 2021-09-01 | Intocell, Inc. | JOINTS WITH SPLITABLE LINKER AND USES THEREOF |
| WO2019229536A2 (en) * | 2018-05-29 | 2019-12-05 | Intocell, Inc. | Novel benzodiazepine derivatives and uses thereof |
| CA3118026A1 (en) * | 2018-10-31 | 2020-05-07 | Intocell, Inc. | Fused heterocyclic benzodiazepine derivatives and uses thereof |
| KR102732027B1 (ko) * | 2019-07-09 | 2024-11-20 | 주식회사 와이바이오로직스 | B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도 |
| AU2021297036A1 (en) | 2020-06-26 | 2023-01-19 | Intocell, Inc. | Antibody-drug conjugates comprising anti-b7-h3 antibodies |
-
2021
- 2021-06-25 AU AU2021297036A patent/AU2021297036A1/en active Pending
- 2021-06-25 EP EP21829799.2A patent/EP4171655A4/en active Pending
- 2021-06-25 JP JP2022580096A patent/JP7798811B2/ja active Active
- 2021-06-25 IL IL299362A patent/IL299362A/en unknown
- 2021-06-25 CN CN202310829257.7A patent/CN116999571A/zh active Pending
- 2021-06-25 CN CN202180050283.9A patent/CN115942978A/zh active Pending
- 2021-06-25 CA CA3182602A patent/CA3182602A1/en active Pending
- 2021-06-25 KR KR1020237002842A patent/KR20230028793A/ko active Pending
- 2021-06-25 WO PCT/IB2021/000445 patent/WO2021260438A1/en not_active Ceased
- 2021-06-25 MX MX2022016180A patent/MX2022016180A/es unknown
- 2021-06-25 BR BR112022026401A patent/BR112022026401A2/pt unknown
- 2021-06-25 US US17/358,306 patent/US12168060B2/en active Active
-
2024
- 2024-09-06 US US18/827,143 patent/US20250121087A1/en active Pending
-
2025
- 2025-12-25 JP JP2025283168A patent/JP2026053657A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523232A5 (enExample) | ||
| TWI847992B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| JP2021063058A5 (enExample) | ||
| CN113710277B (zh) | 一种负载双毒素的抗体药物偶联物及其应用 | |
| JP2025041725A5 (enExample) | ||
| JP2021516976A5 (enExample) | ||
| JP2021516975A5 (enExample) | ||
| JP2022522547A5 (enExample) | ||
| JP7769032B2 (ja) | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| JP2010538972A (ja) | 転移性癌の処置のためのｖｅｇｆｒ−２阻害剤の使用 | |
| JP2021519076A (ja) | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 | |
| EA038192B1 (ru) | Фармацевтические композиции, содержащие диастереомеры макролида, способы их синтезирования и терапевтическое применение | |
| JP2020522281A5 (enExample) | ||
| TWI807320B (zh) | 含有α-烯醇酶抗體之藥物共軛物及其用途 | |
| TW201713365A (zh) | 遞送治療藥物之ｐｈ－敏感性的連接物 | |
| CN115052632B (zh) | 靶向多肽-药物缀合物及其用途 | |
| JP2020533965A5 (enExample) | ||
| EP3906064A1 (en) | Compounds comprising cleavable linker and uses thereof | |
| CN120826405A (zh) | 具有靶向作用的偶联物及其制备方法和用途 | |
| KR20250075746A (ko) | 항체 및 이의 제조 및 사용 방법 | |
| KR20250156815A (ko) | 인간 l1cam에 대한 항체를 포함하는 항체-약물 접합체 및 이의 용도 | |
| JP2025511705A5 (enExample) | ||
| JP2024542879A5 (enExample) | ||
| WO2026098619A1 (zh) | 一种egfr×her3双特异性抗体药物偶联物、其制备方法和应用 | |
| CN119607196A (zh) | 抗lag-3抗体与抗pd-1抗体的应用 |